Research and Development Expenses Breakdown: ADMA Biologics, Inc. vs ImmunityBio, Inc.

Biotech R&D: Divergent Paths of ADMA and ImmunityBio

__timestampADMA Biologics, Inc.ImmunityBio, Inc.
Wednesday, January 1, 201495170141595000
Thursday, January 1, 2015701594611434000
Friday, January 1, 2016768823826546000
Sunday, January 1, 2017622958739778000
Monday, January 1, 2018392612053418000
Tuesday, January 1, 20192343848111997000
Wednesday, January 1, 20205907013139507000
Friday, January 1, 20213646060195958000
Saturday, January 1, 20223613764248149000
Sunday, January 1, 20233300000232366000
Loading chart...

Data in motion

A Tale of Two Innovators: ADMA Biologics, Inc. vs ImmunityBio, Inc.

In the ever-evolving landscape of biotechnology, research and development (R&D) expenses serve as a critical indicator of a company's commitment to innovation. Over the past decade, ADMA Biologics, Inc. and ImmunityBio, Inc. have demonstrated contrasting trajectories in their R&D investments.

From 2014 to 2023, ImmunityBio, Inc. has shown a staggering increase in R&D expenses, growing by over 14,500% from 2014 to 2022, peaking at approximately $248 million. This reflects their aggressive pursuit of cutting-edge therapies. In contrast, ADMA Biologics, Inc. has seen a more modest decline of around 65% in the same period, with expenses dropping from $9.5 million in 2014 to $3.3 million in 2023.

These trends highlight the diverse strategies employed by biotech firms in navigating the challenges and opportunities of the industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025